A Randomized Phase II Trial of Weekly Topotecan With and Without AVE0005 (Aflibercept; NSC-724770) in Patients With Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC).

Trial Profile

A Randomized Phase II Trial of Weekly Topotecan With and Without AVE0005 (Aflibercept; NSC-724770) in Patients With Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC).

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs Aflibercept (Primary) ; Topotecan
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Oct 2015 Status changed from active, no longer recruiting to completed as per results published in JCO 2014
    • 06 Jun 2012 Planned end date changed from 1 Jul 2010 to 1 Jun 2012 as reported by ClinicalTrials.gov.
    • 06 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top